{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:39:02Z","timestamp":1782553142894,"version":"3.54.5"},"reference-count":122,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1053\/j.ackd.2009.07.009","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T15:11:42Z","timestamp":1260544302000},"page":"72-82","source":"Crossref","is-referenced-by-count":52,"title":["Antiretroviral Medications: Adverse Effects on the Kidney"],"prefix":"10.1053","volume":"17","author":[{"given":"Jennifer","family":"Jao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2009.07.009_bib1","unstructured":"UNAIDS 2008 Report on the Global AIDS epidemic. Available at: http:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/GlobalReport\/2008\/2008_Global_report.asp. Accessed May 14, 2009"},{"key":"10.1053\/j.ackd.2009.07.009_bib2","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"Strategies for management of Antiretroviral Therapy (SMART) Study Group: CD4 count\u2013guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/430257","article-title":"Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America","volume":"40","author":"Gupta","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib4","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1124\/dmd.108.020826","article-title":"Relevance of the organic cation transporters 1and 2 for antiretroviral drug therapy in human immunodeficiency virus infection","volume":"36","author":"Jung","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.ackd.2009.07.009_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1124\/jpet.300.3.918","article-title":"Human organic anion transporters and human organic cation transporters mediate renal antiviral transport","volume":"300","author":"Takeda","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1053\/j.ackd.2009.07.009_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1139\/y00-110","article-title":"Uptake properties of lamivudine (3TC) by a continuous renal epithelial cell line","volume":"79","author":"Leung","year":"2001","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1053\/j.ackd.2009.07.009_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1053\/j.ackd.2009.07.009_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11095-006-9196-x","article-title":"Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)","volume":"24","author":"Uwai","year":"2007","journal-title":"Pharm Res"},{"key":"10.1053\/j.ackd.2009.07.009_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/QAD.0b013e328303be50","article-title":"Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy","volume":"22","author":"Nelson","year":"2008","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib10","first-page":"296","article-title":"Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome","volume":"52","author":"Ahmad","year":"2006","journal-title":"J Postgrad Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/ajkd.2000.19114","article-title":"Acute renal failure in an HIV positive 50 year old man","volume":"36","author":"Krishnan","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00002030-199301000-00024","article-title":"Dideoxyinosine-associated nephrotoxicity","volume":"7","author":"Crowther","year":"1993","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib13","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.aids.0000168985.05209.b8","article-title":"Fanconi syndrome associated with didanosine therapy","volume":"19","author":"Izzedine","year":"2005","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib14","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/ndt\/gfm467","article-title":"Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: A case report and literature review","volume":"22","author":"D'Ythurbide","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2009.07.009_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001432-200202000-00005","article-title":"Hyperlactatemia syndromes in people with HIV infection","volume":"15","author":"John","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1128\/AAC.00039-07","article-title":"Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs","volume":"51","author":"Lund","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib17","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/324353","article-title":"Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort Study","volume":"33","author":"Boubaker","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib18","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.48.5.1469-1487.2004","article-title":"Biological effects of short-term or prolonged administration of tenofovir to newborn and infant rhesus macaques","volume":"48","author":"Van Rompay","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14740338.6.2.155","article-title":"Tenofovir-induced kidney injury","volume":"6","author":"Gitman","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.ackd.2009.07.009_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","article-title":"Tenofovir-associated Fanconi syndrome: review of the FDA Adverse Event Reporting System","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib22","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/0091270005281351","article-title":"Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine","volume":"45","author":"Kearney","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2009.07.009_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"Kearney","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions","volume":"42","author":"Zimmerman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","article-title":"Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment","volume":"40","author":"Gallant","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1468-1293.2006.00349.x","article-title":"Minor changes in calculated creatinine clearance and anion-gap are asoociated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy","volume":"7","author":"Winston","year":"2006","journal-title":"HIV Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study","volume":"12","author":"Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1053\/j.ackd.2009.07.009_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1545109707300676","article-title":"Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study","volume":"6","author":"Young","year":"2007","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"10.1053\/j.ackd.2009.07.009_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/QAD.0b013e32801120d1","article-title":"Efavirenz-associated podocyte damage","volume":"21","author":"Barbour","year":"2007","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00240-006-0052-6","article-title":"Efavirenz-induced urolithiasis","volume":"34","author":"Wirth","year":"2006","journal-title":"Urol Res"},{"key":"10.1053\/j.ackd.2009.07.009_bib31","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1097\/QAD.0b013e3282ef792f","volume":"21","author":"Izzedine","year":"2007","journal-title":"Efavirenz urolithiasis. AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib32","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jinf.2005.05.020","article-title":"Severe efavirenz-induced hypersensitivity syndrome (not DRESS) with acute renal failure","volume":"52","author":"Angel-Moreno-Maroto","year":"2006","journal-title":"J Infect"},{"key":"10.1053\/j.ackd.2009.07.009_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1440-1797.2008.00968.x","article-title":"Renal impairment and hypersensitivity reaction due to efavirenz","volume":"13","author":"Curry","year":"2008","journal-title":"Nephrology"},{"key":"10.1053\/j.ackd.2009.07.009_bib34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0029-7844(02)02620-0","article-title":"Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus","volume":"101","author":"Knudtson","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1053\/j.ackd.2009.07.009_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine)in treatment-experienced HIV-1-infected patients in DUET-1: 24 week results from a randomized, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomized, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(05)65125-2","article-title":"Renal failure after treatment with ritonavir","volume":"348","author":"Duong","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib38","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(05)62957-1","article-title":"Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection","volume":"349","author":"Stricker","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib39","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0022-5347(05)65307-4","article-title":"Nelfinavir urinary stones","volume":"167","author":"Engeler","year":"2002","journal-title":"J Urol"},{"key":"10.1053\/j.ackd.2009.07.009_bib40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/135965350801300514","article-title":"Same patient, new stone composition: Amprenavir urinary stone","volume":"13","author":"Feicke","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1053\/j.ackd.2009.07.009_bib41","first-page":"555","article-title":"Renal calculi developing de novo in a patients taking saquinavir","volume":"9","author":"Green","year":"1998","journal-title":"Int J STD AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00002030-200403050-00022","article-title":"Lopinavir\/ritonavir (Kaletra) and lithiasis: seven cases","volume":"18","author":"Doco-Lecompte","year":"2004","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/ajkd.2000.9791","article-title":"Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir","volume":"36","author":"Gagnon","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","article-title":"Crystalluria and urinary tract abnormalities associated with indinavir","volume":"127","author":"Kopp","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-9556(25)06530-4","article-title":"Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine","volume":"23","author":"Balani","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.ackd.2009.07.009_bib46","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archinte.162.13.1493","article-title":"Risk factors for the urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: The ATHENA cohort","volume":"162","author":"Dieleman","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib47","first-page":"261","article-title":"Pyuria in patients treated with indinavir is associated with renal dysfunction","volume":"54","author":"Sarcletti","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2009.07.009_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.2.e19","article-title":"Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir","volume":"110","author":"Van Rossum","year":"2002","journal-title":"Pediatrics"},{"key":"10.1053\/j.ackd.2009.07.009_bib49","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/339486","article-title":"Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings","volume":"99","author":"Kopp","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s15010-001-1105-y","article-title":"Papillary necrosis associated with the HIV protease inhibitor indinavir","volume":"29","author":"Dieleman","year":"2001","journal-title":"Infection"},{"key":"10.1053\/j.ackd.2009.07.009_bib51","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.lpm.2007.05.042","article-title":"N\u00e9crose papillaire bilat\u00e9rale lors d'un traitement par indinavir","volume":"37","author":"Iba-Ba","year":"2008","journal-title":"Presse Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM199902043400515","article-title":"Renal atrophy associated with long-term treatment with indinavir","volume":"340","author":"Hanabusa","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib53","series-title":"Product information","author":"Reyataz","year":"2006"},{"key":"10.1053\/j.ackd.2009.07.009_bib54","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMc061892","article-title":"Atazanavir urolithiasis","volume":"355","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib55","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/01.aids.0000247571.88256.90","article-title":"Atazanavir urinary stones in an HIV-infected patient","volume":"20","author":"Pacanowski","year":"2006","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/QAD.0b013e32813aee35","article-title":"Atazanavir-associated nephrolithiasis: Cases from the US Food and Drug Administration's Adverse Event Reporting System","volume":"21","author":"Chan-Tack","year":"2007","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib57","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1086\/521930","article-title":"Urolithiasis in HIV-positive patients treated with atazanavir","volume":"45","author":"Couzigou","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib58","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0272-6386(04)01093-5","article-title":"Acute interstitial nephritis associated with atazanavir, a new protease inhibitor","volume":"44","author":"Brewster","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1053\/j.ackd.2009.07.009_bib60","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/QAI.0b013e31816237f0","article-title":"Enfuvirtide does not require dose adjustment in patients with chronic kidney failure","volume":"47","author":"Tebas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib61","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib62","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1 infected, treatment-experienced patients: AIDS Clinical Trials Group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib63","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1517\/13543784.15.12.1507","article-title":"A historical sketch of the discovery and development of HIV-1 integrase inhibitors","volume":"15","author":"Savarino","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.ackd.2009.07.009_bib64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","article-title":"Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients","volume":"43","author":"DeJesus","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib66","unstructured":"Zolopa AR, Mullen M, Berger D, et al: The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients [Oral Presentation 143LB]. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007, Los Angeles, CA"},{"key":"10.1053\/j.ackd.2009.07.009_bib67","unstructured":"Zolopa AR, Lampiris H, Blick G, et\u00a0al. The HIV Integrase Inhibitor Elvitegravir (EVG\/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) [Oral Presentation]. Paper presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2007, Chicago, IL"},{"key":"10.1053\/j.ackd.2009.07.009_bib68","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCULATIONAHA.107.189622","article-title":"State of the Science Conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV\/AIDS Executive Summary","volume":"118","author":"Grinspoon","year":"2008","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2009.07.009_bib69","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib70","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-M\u00f8ller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib71","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib72","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors amont patients with human immunodeficiency virus disease","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ackd.2009.07.009_bib73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/QAI.0b013e31815e7251","article-title":"Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy","volume":"47","author":"Bozzette","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib74","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.74.5.1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ackd.2009.07.009_bib75","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2009.07.009_bib76","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/QAI.0b013e318186519c","article-title":"HIV and antiretroviral therapy: Lipid abnormalities and associated cardiovascular risk in HIV-infected patients","volume":"49","author":"Kotler","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib77","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00126334-200303010-00009","article-title":"Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women","volume":"32","author":"Justman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib78","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","article-title":"Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study","volume":"19","author":"Brown","year":"2005","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib79","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Moor","year":"2006","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib80","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2009.07.009_bib82","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients","volume":"29","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2009.07.009_bib83","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","article-title":"Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy","volume":"14","author":"Tebas","year":"2000","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib84","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/00002030-200107060-00009","article-title":"Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir","volume":"15","author":"Nolan","year":"2001","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib85","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","article-title":"Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals","volume":"36","author":"Mondy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1468-1293.2007.00525.x","article-title":"Evolution of bone mineral density in AIDS patients on treatment with zidovudine\/lamivudine plus abacavir or lopinavir\/ritonavir","volume":"9","author":"Rivas","year":"2007","journal-title":"HIV Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib87","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1210\/jc.2003-030767","article-title":"Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children","volume":"89","author":"Mora","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ackd.2009.07.009_bib88","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.qai.0000184860.62189.c8","article-title":"A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children","volume":"40","author":"Giacomet","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib89","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-2525","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children","volume":"118","author":"Gafni","year":"2006","journal-title":"Pediatrics"},{"key":"10.1053\/j.ackd.2009.07.009_bib90","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib91","first-page":"188","article-title":"Hyperkalemic renal tubular acidosis induced by trimethoprim\/sulfamethoxazole in an AIDS patient","volume":"50","author":"Sheehan","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2009.07.009_bib92","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1345\/aph.17042","article-title":"Trimethoprim\/sulfamethoxazole and metabolic acidosis in HIV-infected patients","volume":"32","author":"Porras","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ackd.2009.07.009_bib93","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-119-4-199308150-00008","article-title":"Renal mechanism of trimethoprim-induced hyperkalemia","volume":"119","author":"Velazquez","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib94","first-page":"187","article-title":"Trimethoprim-sulfamethoxazole: Hyperkalemia is an important complication regardless of dose","volume":"46","author":"Perazella","year":"1996","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2009.07.009_bib95","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7326\/0003-4819-124-3-199602010-00006","article-title":"Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole","volume":"124","author":"Alapan","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib96","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/ki.1996.530","article-title":"Reversal of trimethoprim-induced antikaliuresis","volume":"50","author":"Reiser","year":"1996","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2009.07.009_bib97","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00002018-200022030-00006","article-title":"Trimethoprim-induced hyperkalemia: Clinical data, mechanism, prevention, and management","volume":"22","author":"Perazella","year":"2000","journal-title":"Drug Saf"},{"key":"10.1053\/j.ackd.2009.07.009_bib98","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/ajkd.1998.v31.pm9428460","article-title":"Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features","volume":"31","author":"De Vriese","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib99","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/ndt\/13.4.924","article-title":"Rifampicin-induced acute renal failure: A series of 60 patients","volume":"13","author":"Covic","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2009.07.009_bib100","first-page":"622","article-title":"Hearing loss and nephrotoxicity in longterm aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"De Jager","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib101","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib102","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jac\/43.2.267","article-title":"Risk factors for amphotericin B-induced nephrotoxicity","volume":"43","author":"Luber","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib104","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1046\/j.1523-1755.2001.00948.x","article-title":"Correlates of acute renal failure in patients receiving parenteral amphotericin B","volume":"60","author":"Bates","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2009.07.009_bib105","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0272-6386(12)80939-5","article-title":"Rapidly progressive acute renal failure due to acyclovir: A case report and review of the literature","volume":"22","author":"Becker","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"suppl B","key":"10.1053\/j.ackd.2009.07.009_bib106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/12.suppl_B.29","article-title":"Pharmacokinetics of acyclovir after intravenous and oral administration","volume":"12","author":"De Miranda","year":"1983","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib107","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0002-9343(88)90313-0","article-title":"Acyclovir-induced renal failure","volume":"84","author":"Sawyer","year":"1988","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib108","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM199104113241501","article-title":"A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group","volume":"324","author":"Schmidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2009.07.009_bib109","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.ackd.2009.07.009_bib110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.ackd.2009.07.009_bib111","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00042560-199804010-00008","article-title":"Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS","volume":"17","author":"Lalezari","year":"1998","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib112","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/AAC.39.4.882","article-title":"Anticytomegaloviral activity and safety of cidofovir in patients in human immunodeficiency virus infection and cytomegalovirus viruria","volume":"39","author":"Polis","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib113","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2009.07.009_bib114","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.282.24.2305","article-title":"Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial","volume":"282","author":"Kahn","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2009.07.009_bib115","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/00002030-200109070-00013","article-title":"The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: A randomized, placebo-controlled trial","volume":"15","author":"Fisher","year":"2001","journal-title":"AIDS"},{"key":"10.1053\/j.ackd.2009.07.009_bib116","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","article-title":"Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies","volume":"66","author":"Izzedine","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2009.07.009_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/hep.23044","article-title":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil","author":"Ha","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.ackd.2009.07.009_bib118","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: Mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1989","journal-title":"Am J Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2009.07.009_bib119","first-page":"S11","article-title":"Review of the toxicities of foscarnet","volume":"5","author":"Jacobson","year":"1992","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1053\/j.ackd.2009.07.009_bib120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/ajkd.1998.v32.pm9740154","article-title":"Identification of crystals in kidneys of AIDS patients treated with foscarnet","volume":"32","author":"Maurice-Estepa","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib121","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0272-6386(96)90369-8","article-title":"Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy","volume":"27","author":"Navarro","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2009.07.009_bib122","doi-asserted-by":"crossref","first-page":"332","DOI":"10.7326\/0003-4819-113-4-332_1","article-title":"Prevention of foscarnet nephrotoxicity","volume":"113","author":"Deray","year":"1990","journal-title":"Ann Intern Med"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559509001335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559509001335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T19:37:22Z","timestamp":1739475442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559509001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1548559509001335"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2009.07.009","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}